Hostname: page-component-7c8c6479df-995ml Total loading time: 0 Render date: 2024-03-29T07:54:53.033Z Has data issue: false hasContentIssue false

Physiological antagonism between endogenous CCK and opioid: Clinical perspectives in the management of pain

Published online by Cambridge University Press:  01 September 1997

Florence Noble
Affiliation:
Département de Pharmacochimie Moléculaire et Structurale, INSERM U266 – CNRS URA D 1500, Université René Descartes – UFR des Sciences Pharmaceutiques et Biologiques, 75270 Paris Cedex 06, Francemorellet@citi2.fr
Rafaël Maldonado
Affiliation:
Département de Pharmacochimie Moléculaire et Structurale, INSERM U266 – CNRS URA D 1500, Université René Descartes – UFR des Sciences Pharmaceutiques et Biologiques, 75270 Paris Cedex 06, Francemorellet@citi2.fr
Bernard P. Roques
Affiliation:
Département de Pharmacochimie Moléculaire et Structurale, INSERM U266 – CNRS URA D 1500, Université René Descartes – UFR des Sciences Pharmaceutiques et Biologiques, 75270 Paris Cedex 06, Francemorellet@citi2.fr

Abstract

Numerous mediators are involved in both the control and the transmission of nociceptive messages, and several lines of research have been developed in the management of pain. Complete enkephalin- degrading enzyme inhibitors, which produce naloxone-reversible analgesia in all tests where morphine has been found to be active, remains the most promising way. CCK compounds, especially the CCKB antagonists also may be interesting drugs. Indeed, they are able to strongly potentiate the antinociceptive effects of the opioids. [dickenson, wiesenfeld-hallin et al.]

Type
Open Peer Commentary
Copyright
© 1997 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)